The estimated Net Worth of Kimberly J Popovits is at least $19.1 Million dollars as of 5 June 2024. Ms. Popovits owns over 4,373 units of MyoKardia stock worth over $2,108,081 and over the last 19 years she sold MYOK stock worth over $16,612,246. In addition, she makes $350,186 as Independent Director at MyoKardia.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
Ms. Popovits MYOK stock SEC Form 4 insiders trading
Kimberly has made over 74 trades of the MyoKardia stock since 2011, according to the Form 4 filled with the SEC. Most recently she exercised 4,373 units of MYOK stock worth $983,531 on 5 June 2024.
The largest trade she's ever made was selling 60,000 units of MyoKardia stock on 14 August 2018 worth over $3,156,000. On average, Kimberly trades about 5,692 units every 37 days since 2005. As of 5 June 2024 she still owns at least 9,373 units of MyoKardia stock.
You can see the complete history of Ms. Popovits stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Kimberly Popovits biography
Kimberly J. Popovits serves as Independent Director of the Company. From 2009 to 2020, Ms. Popovits served as the chief executive officer of Genomic Health, Inc. (NASDAQ: GHDX), a healthcare company, and from 2012 to 2020, served as chairperson of the Board of Directors of Genomic Health. Prior to that, Ms. Popovits served as president and chief operating officer from February 2002 to January 2009. From November 1987 to February 2002, Ms. Popovits served in various roles at Genentech, Inc., a biotechnology company, most recently serving as senior vice president, marketing and sales from February 2001 to February 2002, and as vice president, sales from October 1994 to February 2001. Prior to joining Genentech, Ms. Popovits served as division manager, southeast region, for American Critical Care, a division of American Hospital Supply, a supplier of healthcare products to hospitals. Ms. Popovits has served on the board of directors of 10x Genomics, Inc. (NASDAQ: TXG) since April 2020 and Kiniksa Pharmaceuticals Corp. (NASDAQ: KNSA) since February 2018. She holds a B.A. in business from Michigan State University. Ms. Popovits’ qualifications to serve on our Board of Directors include her senior management experience in healthcare and biotechnology companies and her many years of experience with commercial strategy and capability building.
What is the salary of Kimberly Popovits?
As the Independent Director of MyoKardia, the total compensation of Kimberly Popovits at MyoKardia is $350,186. There are 10 executives at MyoKardia getting paid more, with Tassos Gianakakos having the highest compensation of $10,223,600.
How old is Kimberly Popovits?
Kimberly Popovits is 61, she's been the Independent Director of MyoKardia since 2017. There are 5 older and 6 younger executives at MyoKardia. The oldest executive at MyoKardia, Inc. is Mary Cranston, 72, who is the Independent Director.
What's Kimberly Popovits's mailing address?
Kimberly's mailing address filed with the SEC is C/O 10X GENOMICS, INC., 6230 STONERIDGE MALL ROAD, PLEASANTON, CA, 94588.
Insiders trading at MyoKardia
Over the last 9 years, insiders at MyoKardia have traded over $313,807,381 worth of MyoKardia stock and bought 2,317,816 units worth $42,556,877 . The most active insiders traders include Sanofi, Kevin P Starr, and Rock Ventures Ii, L.P.Third.... On average, MyoKardia executives and independent directors trade stock every 16 days with the average trade being worth of $21,462,936. The most recent stock trade was executed by Anastasios Gianakakos on 2 July 2020, trading 5,000 units of MYOK stock currently worth $469,900.
What does MyoKardia do?
MyoKardia, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, commercialization, and development of therapies for the treatment of cardiovascular diseases. Its lead therapeutic candidate, Mavacamten, is an orally administered allosteric modulator of cardiac myosin being developed for the treatment of hypertrophic cardiomyopathy (HCM). The company was founded by James A. Spudich, Jonathan G. Seidman, Christine Seidman, and Leslie Leinwand on June 8, 2012 and is headquartered in South San Francisco, CA.
What does MyoKardia's logo look like?
Complete history of Ms. Popovits stock trades at MyoKardia, Kiniksa Pharmaceuticals International Plc, and 10x Genomics
MyoKardia executives and stock owners
MyoKardia executives and other stock owners filed with the SEC include:
-
Tassos Gianakakos,
President, Chief Executive Officer, Director -
William Fairey,
Executive Vice President and Chief Commercial Officer -
Robert McDowell,
Chief Scientific Officer -
Jake Bauer,
Chief Business Officer -
Taylor Harris,
Chief Financial Officer -
Mark Perry,
Non-Executive Independent Chairman of the Board -
Mary Cranston,
Independent Director -
Sunil Agarwal,
Independent Director -
Wendy Yarno,
Independent Director -
David Meeker,
Independent Director -
Kimberly Popovits,
Independent Director -
Michelle Corral,
IR Contact Officer -
Denelle Waynick,
General Counsel, Corporate Secretary -
Rock Ventures Ii, L.P.Third...,
-
Sanofi,
10% owner -
Eric Topol,
Director -
Anastasios Gianakakos,
President and CEO -
Joseph Lambing,
See Remarks -
Marc Semigran,
Chief Medical Officer -
Kevin P Starr,
Director -
Steven Chan,
See Remarks -
Charles J Homcy,
Director -
June Lee,
EVP, Chief Development Officer -
Jonathan C Fox,
Chief Medical Officer -
Rock Ventures Iii, L.P.Thir...,
-
Cynthia J Ladd,
General Counsel -
Rock Ventures Ii, L.P.Third...,